SCHEMBL2648424

SCHEMBL2648424

N#Cc1c(N)sc2c1CCCC2c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 2/20 0.44
MET P08581 1/20 0.44
ALDH1A1 P00352 10/20 0.43
MAPT P10636 8/20 0.43
HSD17B10 Q99714 8/20 0.43
GAA P10253 4/20 0.43
ALOX15 P16050 4/20 0.43
MAPK1 P28482 2/20 0.43
MEN1 O00255 6/20 0.42
KMT2A Q03164 6/20 0.42
CASP1 P29466 3/20 0.42
POLB P06746 2/20 0.42
PABPC1 P11940 1/20 0.42
KRAS P01116 1/20 0.41
KDM4E B2RXH2 8/20 0.41
HPGD P15428 4/20 0.41
TDP1 Q9NUW8 2/20 0.41
RECQL P46063 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ADORA1 P30542 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20254478 0.70 MAPT (0.49) BPTFMETALDH1A1MAPTHSD17B10
SCHEMBL8281571 0.66 MAPT (0.50) ALDH1A1MAPTHSD17B10GAAALOX15
SCHEMBL2658305 0.66 ALDH1A1 (0.47) BPTFALDH1A1MAPTHSD17B10GAA
SCHEMBL12643259 0.63 BPTF (0.39) BPTFMETALDH1A1MAPTHSD17B10
SCHEMBL620749 0.62 BPTF (1.00) BPTFALDH1A1MAPTHSD17B10GAA
SCHEMBL1514467 0.62 BPTF (0.92) BPTFALDH1A1MAPTHSD17B10GAA
SCHEMBL27855310 0.62 ALDH1A1 (0.43) ALDH1A1MAPTHSD17B10GAAALOX15
SCHEMBL31381502 0.61 BPTF (0.96) BPTFALDH1A1MAPTHSD17B10GAA
SCHEMBL1719516 0.61 ALDH1A1 (1.00) BPTFALDH1A1MAPTHSD17B10GAA
SCHEMBL31684745 0.61 IGF1R (0.47) ALOX15MAPK1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060035958-A1 Method of treating diabetes and related conditions MERCK & CO., INC. 2006-02-16 US disclosed
EP-1538903-A2 METHOD OF TREATING DIABETES AND RELATED CONDITIONS Merck & Co., Inc. (US) 2005-06-15 EP disclosed
WO-2004024066-A2 METHOD OF TREATING DIABETES AND RELATED CONDITIONS MERCK & CO., INC. (US) 2004-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035958-A1 Method of treating diabetes and related conditions GLP1R, GPR119, GCGR BPTF 4242/4885MET 1026/4885ALDH1A1 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.